[Efficacy and tolerability of pregabalin in patients with neuropathic pain. Observational study under clinical practice conditions].
Mallison
R
R
Medical Affairs, Pfizer Pharma GmbH, Postfach 4949, D-76032 Karlsruhe.
Tilke
C
C
Brasser
M
M
Pittrow
D
D
D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D015220:Calcium Channels / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy / Q000209:etiology; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D000069583:Pregabalin; D011446:Prospective Studies; D011843:Radiculopathy / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000700:Analgesics; D015220:Calcium Channels; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid